| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.094 | 0.06 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.078 | 0.06 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.082 | 0.07 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.07 |
| mRNA | JQ-1:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.098 | 0.07 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |